Filing Flows › Companies › Pacira BioSciences › Timeline
Pacira BioSciences stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+72.6% to $36.43
Pacira BioSciences (PCRX) stock rose 73% over the last 252 sessions, to $36.43. On the way it reported 0 quarters, its insiders filed 1 open-market trade and 2 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 8, 2026 | 8-K | Material definitive agreement | +36.7% (+37.2% vs SPY) | +36.8% (+37.8% vs SPY) | +36.8% (+42.7% vs SPY) |
| Oct 8, 2026 | Form 144 | Form 144: Lauren Riker plans to sell $218K | +36.7% (+37.2% vs SPY) | +36.8% (+37.8% vs SPY) | +36.8% (+42.7% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Jonathan Slonin plans to sell $71K | +1.0% (+1.5% vs SPY) | +7.0% (+8.4% vs SPY) | +4.6% (+7.1% vs SPY) |
| Jun 30, 2026 | 8-K | Material definitive agreement | +1.1% (+0.3% vs SPY) | +2.9% (+2.0% vs SPY) | +5.1% (+6.6% vs SPY) |
| Jun 11, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.6% (−2.1% vs SPY) | −4.5% (−6.0% vs SPY) | +6.8% (+4.7% vs SPY) |
| Mar 17, 2026 | Insider sale | Froimson Mark sold $11K | −3.4% (−3.6% vs SPY) | −0.2% (+1.6% vs SPY) | +3.2% (−1.6% vs SPY) |
| Jan 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.6% (+2.7% vs SPY) | +5.7% (+6.6% vs SPY) | +12.9% (+13.8% vs SPY) |
Insiders’ record here
In the year on the chart, Pacira BioSciences' insiders reported 0 open-market buys ($0) and 1 sale ($11K). Of the 1 old enough to score, 1 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −7.8%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Pacira BioSciences: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.